Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 and Increased Inflammatory Markers: a Phase III Randomized Clinical Trial (COVID-19 Coalition Brazil VI) (TOCIBRAS)

NCT04403685 is registered in ClinicalTrials.gov with Beneficência Portuguesa de São Paulo as lead sponsor.

NCT NCT04403685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04403685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 and Increased Inflammatory Markers: a Phase III Randomized Clinical Trial (COVID-19 Coalition Brazil VI) (TOCIBRAS)
Lead sponsor
Beneficência Portuguesa de São Paulo
Phase
Phase 3
Overall status
Terminated
Start date
May 8, 2020
Completion date
July 21, 2020
Enrollment
129 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

covid, cytokine release syndrome, sars pneumonia